Create your Personal Health Record and unlock support built around you
- Treatments and trials you qualify for
- Education for your stage of care
- Financial support for your medications
- Solutions to your side effects
MPN Updates from EHA 2026: Five Major Treatment Breakthroughs #MPN
HealthTreeDescription
Dr. Claire Harrison from Guy's and St. Thomas's Hospital, London—EHA Lifetime Achievement Award recipient—presents five major MPN treatment advances from EHA 2026, covering updates for ET (essential thrombocythemia), PV (polycythemia vera), and myelofibrosis.
FIVE KEY UPDATES:
1. SELINEXOR + RUXOLITINIB (CENTURY Trial)
- Doubles spleen responses
- 50% reduction in death risk at 6 months
- Well tolerated with manageable side effects
- Week 48 data coming soon
2. CALRETICULIN (CALR) IMMUNE THERAPY
- New approach for CALR-mutated MPN
- Works by targeting abnormal protein on cancer cells
- Excellent tolerability: 30-minute infusion
- Patients age 30-83 benefiting
- Bone marrow normalization observed in myelofibrosis
3. AJAX DRUG (Mutation-Specific JAK Inhibitor)
- More precisely targets JAK2 mutation
- Reduces mutation burden by 50%+ = survival benefit
- Strong tolerability and response rates
- Just acquired by Lilly
4. LUSPATERCEPT (For Anemia)
- Addresses anemia side effect of JAK inhibitors
- Combined with JAK inhibitors shows strong benefit
- Used in MDS, now showing promise in MPN
5. G6B (Emerging Target)
- New discovery from Oxford University
- Targets all MPN cells regardless of mutation type
- Watch for future studies
THE BIG PICTURE:
MPN treatment is evolving from symptom management to disease modification—reducing mutations, normalizing bone marrow, and improving survival.
Learn more: https://linktr.ee/HealthTreeUniversity
TIMESTAMPS:
0:00 Introduction & EHA Award Winner
0:18 Updates for ET, PV & Myelofibrosis
0:26 MPN Community Collaboration
1:23 Four Main Treatment Updates
1:31 #1: CENTURY Study - Selinexor + Ruxolitinib
2:40 Key Results: Spleen Responses & Survival
4:23 #2: Calreticulin Immune Therapy
5:33 CALR Therapy Results & Bone Marrow Normalization
6:27 #3: AJAX Drug - Mutation-Specific JAK Inhibitor
7:10 #4: Luspatercept for Anemia
7:34 #5: G6B - New Emerging Target
8:01 Closing: Future of MPN Treatment
#MPN #EHA2026 #ET #PV #Myelofibrosis #NewTreatments